These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22648253)

  • 1. A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration.
    Nowak MS; Jurowski P; Grzybowski A; Goś R; Pastuszka M; Kapica A; Śmigielski J
    Med Sci Monit; 2012 Jun; 18(6):CR374-80. PubMed ID: 22648253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
    Hamon F; Goeminne P
    Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Ahadi H
    Eur J Ophthalmol; 2008; 18(2):297-300. PubMed ID: 18320527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
    Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
    Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
    Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
    Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot trial for comparison of photodynamic therapy and transpupillary thermotherapy for the management of classic subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Tewari HK; Prakash G; Azad RV; Talwar D; Kai S
    Indian J Ophthalmol; 2007; 55(4):277-81. PubMed ID: 17595476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration.
    Odergren A; Algvere PV; Seregard S; Libert C; Kvanta A
    Acta Ophthalmol; 2010 Jun; 88(4):426-30. PubMed ID: 20597872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.
    Chan WM; Lai TY; Wong AL; Tong JP; Liu DT; Lam DS
    Br J Ophthalmol; 2006 Mar; 90(3):337-41. PubMed ID: 16488958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.